{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T13:12:13Z","timestamp":1782393133626,"version":"3.54.5"},"reference-count":17,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2020,8,7]],"date-time":"2020-08-07T00:00:00Z","timestamp":1596758400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Reports"],"published-print":{"date-parts":[[2020,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Tyrosine\u2010kinase inhibitor (TKI) drugs have been considered first line treatment for metastatic renal cell cancer (RCC) for over a decade. TKI\u2010induced hypertension is a common adverse\u2010event in patients treated for metastatic RCC.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aim<\/jats:title><jats:p>This study was aimed at investigating an association between TKI\u2010induced hypertension and treatment outcomes for metastatic RCC patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods and results<\/jats:title><jats:p>Retrospective data pertaining to patients with histologically or radiologically confirmed metastatic RCC treated with sunitinib, pazopanib, sorafenib, axitinib or cabozantinib between June 2012 and May 2019 were evaluated. Clinical information and serial blood pressure measurements were extracted from medical records for each patient. We compared objective response rate, progression\u2010free survival (PFS), and 12\u2010month survival between TKI\u2010induced hypertension (TIH) and non\u2010TIH groups using <jats:italic>\u03c7<\/jats:italic><jats:sup>2<\/jats:sup> and Mann\u2010Whitney tests.<\/jats:p><jats:p>Out of 72 patients screened, 52 met study eligibility criteria. The median age at diagnosis was 61\u2009years (range: 42\u201085\u2009years) with a clear male predominance. The majority of patients had a history of nephrectomy with clear cell pathology. Almost all patients were on first\u2010line TKI therapy with sunitinib or pazopanib. Median follow\u2010up was 11\u2009months. About half of patients developed TKI\u2010induced hypertension (grade 2\u20103). In the TIH group 82% were commenced on an antihypertensive agent. Median PFS measured 30.5\u2009weeks for TIH group compared to 22.2\u2009weeks for non\u2010TIH (<jats:italic>P<\/jats:italic> =\u2009.05). The 6 month and 12\u2009month survival rates for TIH were 82% and 56%, respectively, as compared to 76% and 44% for non\u2010TIH.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The occurrence of TKI\u2010induced hypertension was found to be a positive prognostic factor for progression in patients with metastatic RCC.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cnr2.1275","type":"journal-article","created":{"date-parts":[[2020,8,7]],"date-time":"2020-08-07T15:26:10Z","timestamp":1596813970000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Association between tyrosine\u2010kinase inhibitor induced hypertension and treatment outcomes in metastatic renal cancer"],"prefix":"10.1002","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1390-0756","authenticated-orcid":false,"given":"Monique","family":"Gadd","sequence":"first","affiliation":[{"name":"Australian National University Medical School Australian National University  Acton Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ganes","family":"Pranavan","sequence":"additional","affiliation":[{"name":"Australian National University Medical School Australian National University  Acton Australia"},{"name":"Department of Medical Oncology The Canberra Hospital  Garran Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laeeq","family":"Malik","sequence":"additional","affiliation":[{"name":"Australian National University Medical School Australian National University  Acton Australia"},{"name":"Department of Medical Oncology The Canberra Hospital  Garran Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,8,7]]},"reference":[{"key":"e_1_2_11_2_1","volume-title":"Cancer in Australia 2019","author":"Australian Institute of Health and Welfare","year":"2019"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00261-016-0692-0"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0094-0143(03)00056-9"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2018.08.036"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1601333"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1510665"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1816714"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2007.12.001"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12894-019-0481-5"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.50.8267"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt288"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djr128"},{"key":"e_1_2_11_14_1","unstructured":"National Heart Foundation of Australia. Guideline for the diagnosis and management of hypertension in adults 2016.Melbourne:National Heart Foundation of Australia;2016."},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/1744-9987.12537"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0055128"},{"key":"e_1_2_11_17_1","first-page":"559","article-title":"Acne\u2010like rash predicts response in patients treated with cetuximab (IMC\u2010C225) plus irinotecan (CPT\u201011) in CPT\u201011\u2010refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR)","author":"Saltz LHH","year":"2001","journal-title":"Proc NCI\u2010AACR\u2010EORTC"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2016-000045"}],"container-title":["Cancer Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcnr2.1275","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cnr2.1275","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cnr2.1275","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cnr2.1275","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T06:52:25Z","timestamp":1693810345000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cnr2.1275"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,7]]},"references-count":17,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["10.1002\/cnr2.1275"],"URL":"https:\/\/doi.org\/10.1002\/cnr2.1275","archive":["Portico"],"relation":{},"ISSN":["2573-8348","2573-8348"],"issn-type":[{"value":"2573-8348","type":"print"},{"value":"2573-8348","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,7]]},"assertion":[{"value":"2020-04-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-07-02","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-08-07","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e1275"}}